MA43738A - Anticorps anti-tnfalpha et leurs fragments fonctionnels - Google Patents

Anticorps anti-tnfalpha et leurs fragments fonctionnels

Info

Publication number
MA43738A
MA43738A MA043738A MA43738A MA43738A MA 43738 A MA43738 A MA 43738A MA 043738 A MA043738 A MA 043738A MA 43738 A MA43738 A MA 43738A MA 43738 A MA43738 A MA 43738A
Authority
MA
Morocco
Prior art keywords
functional fragments
tnfalpha antibodies
tnfalpha
antibodies
fragments
Prior art date
Application number
MA043738A
Other languages
English (en)
Inventor
Esther Maria Furrer
Tea Gunde
Sebastian Meyer
Original Assignee
Tillotts Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tillotts Pharma Ag filed Critical Tillotts Pharma Ag
Publication of MA43738A publication Critical patent/MA43738A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA043738A 2016-03-17 2017-03-16 Anticorps anti-tnfalpha et leurs fragments fonctionnels MA43738A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16160918.5A EP3219727B1 (fr) 2016-03-17 2016-03-17 Anticorps anti-tnf alpha et fragments fonctionnels de ceux-ci

Publications (1)

Publication Number Publication Date
MA43738A true MA43738A (fr) 2018-11-28

Family

ID=55542579

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043738A MA43738A (fr) 2016-03-17 2017-03-16 Anticorps anti-tnfalpha et leurs fragments fonctionnels

Country Status (27)

Country Link
US (1) US10975143B2 (fr)
EP (2) EP3219727B1 (fr)
JP (1) JP7126485B2 (fr)
KR (1) KR102474765B1 (fr)
CN (1) CN109071651B (fr)
AR (1) AR107916A1 (fr)
BR (1) BR112018067713A2 (fr)
CA (1) CA3011786C (fr)
CY (1) CY1123781T1 (fr)
DK (1) DK3219727T3 (fr)
EA (1) EA201892097A1 (fr)
ES (1) ES2843974T3 (fr)
HR (1) HRP20210120T1 (fr)
HU (1) HUE052869T2 (fr)
IL (1) IL261140B2 (fr)
JO (1) JOP20170063B1 (fr)
LT (1) LT3219727T (fr)
MA (1) MA43738A (fr)
PL (1) PL3219727T3 (fr)
PT (1) PT3219727T (fr)
RS (1) RS61412B1 (fr)
SG (1) SG11202000029PA (fr)
SI (1) SI3219727T1 (fr)
SM (1) SMT202000703T1 (fr)
TW (1) TWI758280B (fr)
UY (1) UY37158A (fr)
WO (1) WO2017158097A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10787508B2 (en) 2016-03-17 2020-09-29 Numab Innovation Ag Anti-TNFα-antibodies and functional fragments thereof
EP3219726B1 (fr) 2016-03-17 2020-12-02 Tillotts Pharma AG Anticorps anti-tnf alpha et fragments fonctionnels de ceux-ci
BR112018017165A2 (pt) 2016-03-17 2019-01-02 Numab Innovation Ag anticorpos anti-tnf-alfa e fragmentos funcionais dos mesmos
KR102616436B1 (ko) 2016-12-14 2023-12-27 비오라 쎄라퓨틱스, 인크. Tnf 저해제로의 위장관 질환의 치료
WO2018162724A1 (fr) * 2017-03-09 2018-09-13 Mab Discovery Gmbh Anticorps se liant spécifiquement à il-1r7 humain
EP3810095A1 (fr) 2018-06-20 2021-04-28 Progenity, Inc. Traitement d'une maladie du tractus gastro-intestinal avec un inhibiteur du tnf
WO2020051275A1 (fr) * 2018-09-05 2020-03-12 The Board Of Regents Of The University Of Texas System Anticorps monoclonaux contre l'endotrophine et leur utilisation
CN116726361A (zh) 2018-11-19 2023-09-12 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
WO2020114616A1 (fr) 2018-12-07 2020-06-11 Tillotts Pharma Ag Traitement topique d'une diarrhée, d'une colite ou d'une entérocolite induite par un inhibiteur de point de contrôle immunitaire au moyen d'anticorps et de fragments de ceux-ci
WO2021119482A1 (fr) 2019-12-13 2021-06-17 Progenity, Inc. Dispositif ingérable pour administrer un agent thérapeutique dans le tractus gastro-intestinal

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
GB9109645D0 (en) 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US5919452A (en) 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
NO309690B1 (no) 1995-01-23 2001-03-12 Western Atlas Int Inc Detonasjonsanordning av type eksploderende brotråd for bruk med et perforeringsverktöy i en brönn
EP0822830B1 (fr) 1995-04-27 2008-04-02 Amgen Fremont Inc. Anticorps anti-IL-8 dérivés de xenosouris immunisées
CA2219486A1 (fr) 1995-04-28 1996-10-31 Abgenix, Inc. Anticorps humains derives de xeno-souris immunisees
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP2305027B1 (fr) 1996-12-03 2014-07-02 Amgen Fremont Inc. Mammifères trangèniques obtenus par génie génétique contenant des loci des immunoglobulines humaines qui comprennent plusieurs régions de VH et de Vkappa, et anticorps aussi obtenus.
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
SI0970126T1 (en) 1997-04-14 2001-08-31 Micromet Ag Novel method for the production of antihuman antigen receptors and uses thereof
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
EP1135498B1 (fr) 1998-11-18 2008-01-23 Genentech, Inc. Variants d'anticorps a affinite de liaison superieure par rapport aux anticorps d'origine
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
US7431927B2 (en) 2005-03-24 2008-10-07 Epitomics, Inc. TNFα-neutralizing antibodies
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
JP5089582B2 (ja) 2005-06-07 2012-12-05 エスバテック、アン アルコン バイオメディカル リサーチ ユニット、エルエルシー ＴＮＦαを阻害する安定な可溶性抗体
RU2653753C1 (ru) 2008-06-25 2018-05-14 ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи СТАБИЛЬНЫЕ И РАСТВОРИМЫЕ АНТИТЕЛА, ИНГИБИРУЮЩИЕ TNFα
CN104004094B (zh) 2008-06-25 2017-09-22 艾斯巴技术-诺华有限责任公司 使用通用抗体构架进行的兔抗体的人源化
US8697074B2 (en) 2008-07-10 2014-04-15 Esbatech, An Alcon Biomedical Research Unit Llc Methods and compositions for enhanced delivery of macromolecules
CN102958537B (zh) * 2010-04-07 2015-09-16 Abbvie公司 TNF-α结合蛋白
AU2011277983C1 (en) * 2010-07-16 2016-09-29 Ablynx Nv Modified single domain antigen binding molecules and uses thereof
AU2011307886C1 (en) * 2010-09-30 2015-07-09 Chengdu Kanghong Biotechnologies Co., Ltd. Anti TNF alpha humanized antibody and fragment antigen binding (Fab) and use thereof
WO2012057288A1 (fr) * 2010-10-29 2012-05-03 第一三共株式会社 Nouvel anticorps anti-dr5
HUE053669T2 (hu) * 2012-12-05 2021-07-28 Novartis Ag Készítmények és eljárások EPO-t célzó antitestekre
IL243311B (en) 2013-06-26 2022-07-01 Numab Therapeutics AG New frameworks for antibodies
CA2924520C (fr) * 2013-11-01 2023-09-26 Ibc Pharmaceuticals, Inc. Anticorps bispecifiques qui neutralisent a la fois tnf-alpha et il-6 : nouvel agent therapeutique pour traiter une maladie auto-immune
US9737623B2 (en) * 2013-12-11 2017-08-22 Cytomx Therapeutics, Inc. Antibodies that bind activatable antibodies and methods of use thereof
CA2943445A1 (fr) * 2014-03-26 2015-10-01 Cell Medica Switzerland Ag Elements de liaison diriges contre tnf alpha
US10787508B2 (en) 2016-03-17 2020-09-29 Numab Innovation Ag Anti-TNFα-antibodies and functional fragments thereof
EP3219726B1 (fr) 2016-03-17 2020-12-02 Tillotts Pharma AG Anticorps anti-tnf alpha et fragments fonctionnels de ceux-ci
BR112018017165A2 (pt) 2016-03-17 2019-01-02 Numab Innovation Ag anticorpos anti-tnf-alfa e fragmentos funcionais dos mesmos

Also Published As

Publication number Publication date
IL261140A (en) 2018-10-31
EP3219727A1 (fr) 2017-09-20
PL3219727T3 (pl) 2021-05-17
SI3219727T1 (sl) 2021-04-30
US20200299375A1 (en) 2020-09-24
EP3430045B1 (fr) 2023-08-23
RS61412B1 (sr) 2021-03-31
CY1123781T1 (el) 2022-05-27
CN109071651A (zh) 2018-12-21
CN109071651B (zh) 2022-08-30
IL261140B2 (en) 2023-04-01
TW201739765A (zh) 2017-11-16
EP3430045A1 (fr) 2019-01-23
IL261140B (en) 2022-12-01
JP7126485B2 (ja) 2022-08-26
CA3011786C (fr) 2025-06-03
LT3219727T (lt) 2021-02-10
ES2843974T3 (es) 2021-07-21
HRP20210120T1 (hr) 2021-03-05
EA201892097A1 (ru) 2019-02-28
WO2017158097A1 (fr) 2017-09-21
JP2019512269A (ja) 2019-05-16
BR112018067713A2 (pt) 2019-01-08
KR20180118671A (ko) 2018-10-31
TWI758280B (zh) 2022-03-21
SMT202000703T1 (it) 2021-01-05
CA3011786A1 (fr) 2017-09-21
HUE052869T2 (hu) 2021-05-28
PT3219727T (pt) 2021-01-21
JOP20170063B1 (ar) 2021-08-17
SG11202000029PA (en) 2020-02-27
KR102474765B1 (ko) 2022-12-06
DK3219727T3 (da) 2021-01-04
AR107916A1 (es) 2018-06-28
UY37158A (es) 2017-10-31
US10975143B2 (en) 2021-04-13
EP3219727B1 (fr) 2020-12-16

Similar Documents

Publication Publication Date Title
FR25C1020I1 (fr) Anticorps thérapeutiques et leurs utilisations
EP3626825A4 (fr) Anticorps anti-cdh6 et conjugué anticorps anti-cdh6-médicament
MA46525A (fr) Anticorps anti-lag-3 et compositions
EP3589313A4 (fr) Anticorps anti-tigit
MA49034A (fr) Anticorps anti-lag3
MA44659A (fr) Anticorps anti-tim-3 et compositions
EP3504243A4 (fr) Anticorps anti-tim-3 et leurs utilisations
MA47268A (fr) Anticorps anti-gpc3
EP3397276A4 (fr) Anticorps et conjugués de ceux-ci
EP3498840A4 (fr) Anticorps anti-lag-3
EP3426686A4 (fr) Anticorps anti-pacap humanisés et leurs utilisations
MA49537A (fr) Anticorps anti-lag3 et leurs utilisations
EP3423089A4 (fr) Anticorps anti-tigit
MA46704A (fr) Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations
EP3328895A4 (fr) Anticorps anti-pd-l1 et leurs utilisations
DK3307274T3 (da) Anti-cd123-antistoffer og konjugater deraf
MA43738A (fr) Anticorps anti-tnfalpha et leurs fragments fonctionnels
EP3283517A4 (fr) Anticorps anti-pacap et leurs utilisations
DK3532499T3 (da) ANTI-IL-33-antistoffer og anvendelser deraf
DK3402821T3 (da) Psma-bindende antistof og anvendelser deraf
MA45125A (fr) Anticorps anti-alpha-synucléine et leurs utilisations
EP3492591A4 (fr) Anticorps anti-b7-h4
EP3526247A4 (fr) Anticorps anti-il1-rap
EP3617231A4 (fr) Anticorps anti-gpc-1
EP3399992A4 (fr) Anticorps autoréticulants